
Our first therapy
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)
Prostate cancer
A prescription radioligand therapy approved for adults with PSMA-positive metastatic prostate cancer, either (1) together with an androgen receptor pathway inhibitor (ARPI) when the cancer has not been treated with, or is still responding to, hormone therapy, or (2) after ARPI therapy when the cancer no longer responds to hormone therapy, whether taxane chemotherapy has already been given or is being delayed. The Prescribing Information lists the full approved uses.
Given by IV, typically once every 6 weeks for up to 6 doses.
Talk with your doctor to see if this treatment is right for you.
Prescribing Information for Pluvicto® (PDF) pluvicto.com, the official Pluvicto® patient site





